Head to Head Analysis: Tonix Pharmaceuticals (TNXP) versus Innovus Pharmaceuticals (INNV)

Innovus Pharmaceuticals (OTCMKTS: INNV) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.

Institutional and Insider Ownership

17.5% of Tonix Pharmaceuticals shares are owned by institutional investors. 19.1% of Innovus Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Innovus Pharmaceuticals has a beta of 4.02, meaning that its share price is 302% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Innovus Pharmaceuticals and Tonix Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovus Pharmaceuticals 0 0 0 0 N/A
Tonix Pharmaceuticals 0 1 4 0 2.80

Tonix Pharmaceuticals has a consensus target price of $8.33, suggesting a potential upside of 107.30%. Given Tonix Pharmaceuticals’ higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Innovus Pharmaceuticals.

Earnings and Valuation

This table compares Innovus Pharmaceuticals and Tonix Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innovus Pharmaceuticals $4.82 million 3.07 -$13.70 million ($0.07) -1.29
Tonix Pharmaceuticals N/A N/A -$38.84 million ($4.77) -0.84

Innovus Pharmaceuticals has higher revenue and earnings than Tonix Pharmaceuticals. Innovus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Innovus Pharmaceuticals and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innovus Pharmaceuticals -102.95% -330.39% -72.75%
Tonix Pharmaceuticals N/A -78.25% -73.14%

Summary

Innovus Pharmaceuticals beats Tonix Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Receive News & Ratings for Innovus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply